|
1.
|
|
10 p, 345.6 KB |
Momelotinib long-term safety and survival in myelofibrosis : integrated analysis of phase 3 randomized controlled trials
/
Verstovsek, Srdan (The University of Texas, USA) ;
Mesa, Ruben (UT Health San Antonio Cancer Center, San Antonio, USA) ;
Gupta, Vikas (Princess Margaret Cancer Centre, Toronto, Canada) ;
Lavie, David (Hadassah-Hebrew University Medical Center, Jerusalem, Israel) ;
Dubruille, Viviane (Centre Hospitalier Universitaire de Nantes (CHU de Nantes), Nantes, France) ;
Cambier, Nathalie (Centre hospitalier r ' egional universitaire de Lille (CHRU Lille), Lille, France) ;
Platzbecker, Uwe (University of Leipzig, Germany) ;
Hus, Marek (Uniwersytet Medyczny w Lublinie, Lublin, Poland) ;
Xicoy, Blanca (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras) ;
Oh, Stephen T. (Washington University School of Medicine, St. Louis, USA) ;
Kiladjian, Jean Jacques (Universite de Paris, France) ;
Vannucchi, Alessandro M. (University of Florence, Careggi University Hospital, Florence, Italy) ;
Gerds, Aaron (Cleveland Clinic, USA) ;
Egyed, Miklos (Teaching Hospital Mor Kaposi, Kaposv ' ar, Hungary) ;
Mayer, Jiří (Masaryk University, Brno, Czech Republic) ;
Sacha, Tomasz (Uniwersytet Jagiellonski Collegium Medicum, Krakow, Poland) ;
Kawashima, Jun (Sierra Oncology, San Mateo, CA) ;
Morris, Marc (Sierra Oncology, San Mateo, CA) ;
Huang, Mei (Sierra Oncology, San Mateo, CA) ;
Harrison, Claire (National Health Services (NHS) Foundation Trust, London, United Kingdom)
Momelotinib is the first inhibitor of Janus kinase 1 (JAK1) and JAK2 shown to also inhibit activin A receptor type 1 (ACVR1), a key regulator of iron homeostasis, and has demonstrated improvements in splenomegaly, constitutional symptoms, and anemia in myelofibrosis (MF). [...]
2023 -  10.1182/bloodadvances.2022009311
Blood advances, Vol. 7 Núm. 14 (july 2023) , p. 3582-3591
|
|
|
2.
|
|
12 p, 506.4 KB |
Results from a First-in-Human Phase I Study of Siremadlin (HDM201) in Patients with Advanced Wild-Type TP53 Solid Tumors and Acute Leukemia
/
Stein, Eytan M. (Memorial Sloan Kettering Cancer Center (New York)) ;
DeAngelo, Daniel J. (Dana-Farber Cancer Institute (Boston, Massachusetts)) ;
Chromik, Jörg (Goethe University Frankfurt) ;
Chatterjee, Manik (University Hospital of Würzburg) ;
Bauer, Sebastian (German Consortium of Translational Cancer Research (DKTK)) ;
Lin, Chia-Chi (National Taiwan University Hospital (Taipei, Taiwan)) ;
Suárez, Cristina (Vall d'Hebron Institut d'Oncologia) ;
de Vos, Filip (University Medical Center Utrecht) ;
Steeghs, Neeltje (The Netherlands Cancer Institute (Amsterdam, Països Baixos)) ;
Cassier, Philippe A. (Léon Bérard Center) ;
Tai, David (National Cancer Center Singapore) ;
Kiladjian, Jean-Jacques (Université de Paris) ;
Yamamoto, Noboru (National Cancer Center Hospital (Tokyo, Japó)) ;
Mous, Rogier (University Medical Center Utrecht) ;
Esteve Reyner, Jordi (Hospital Clínic i Provincial de Barcelona) ;
Minami, Hironobu (Kobe University Graduate School of Medicine and Hospital (Japó)) ;
Ferretti, Stephane (Novartis Institutes for Biomedical Research) ;
Guerreiro, Nelson (Novartis Institutes for Biomedical Research) ;
Meille, Christophe (Novartis Institutes for Biomedical Research) ;
Radhakrishnan, Rajkumar (Novartis Healthcare Private Limited (Hyderabad, India)) ;
Pereira, Bernard (Novartis Institutes for BioMedical Research (Cambridge, Massachusetts)) ;
Mariconti, Luisa (Novartis Institutes for Biomedical Research) ;
Halilovic, Ensar (Novartis Institutes for BioMedical Research (Cambridge, Massachusetts)) ;
Fabre, Claire (Novartis Institutes for Biomedical Research) ;
Carpio Segura, Cecilia del Carmen (Vall d'Hebron Institut d'Oncologia) ;
Universitat Autònoma de Barcelona
This phase I, dose-escalation study investigated the recommended dose for expansion (RDE) of siremadlin, a p53-MDM2 inhibitor, in patients with wild-type TP53 advanced solid or hematologic cancers. Initial dosing regimens were: 1A (day 1; 21-day cycle; dose 12. [...]
2021 - 10.1158/1078-0432.CCR-21-1295
Clinical Cancer Research, Vol. 28 (december 2021) , p. 870-881
|
|
|
3.
|
|
6 p, 790.6 KB |
Breakthrough infections in MPN-COVID vaccinated patients
/
Barbui, Tiziano (Papa Giovanni XXIII Hospital) ;
Carobbio, Alessandra (Papa Giovanni XXIII Hospital) ;
Ghirardi, Arianna (Papa Giovanni XXIII Hospital) ;
Iurlo, Alessandra (Foundation IRCCS Ca' Granda Ospedale Maggiore Policlinico) ;
De Stefano, Valerio (Università Cattolica del Sacro Cuore) ;
Sobas, Marta Anna (Wroclaw Medical University) ;
Rumi, Elisa (University of Pavia) ;
Elli, Elena Maria (Ospedale San Gerardo (Itàlia)) ;
Lunghi, Francesca (IRCCS Ospedale San Raffaele) ;
Gasior Kabat, Mercedes (Hospital Universitario La Paz (Madrid)) ;
Cuevas, Beatriz (Hospital Universitario de Burgos) ;
Guglielmelli, Paola (University of Florence) ;
Bonifacio, Massimiliano (University of Verona (Itàlia)) ;
Marchetti, Monia (AOU SS.Antonio e Biagio e C.Arrigo, Alessandria, Italy) ;
Alvarez-Larran, Alberto (Hospital Clínic i Provincial de Barcelona) ;
Fox, Maria Laura (Vall d'Hebron Institut d'Oncologia) ;
Bellini, Marta (ASST Papa Giovanni XXIII) ;
Daffini, Rosa (ASST-Spedali Civili) ;
Benevolo, Giulia (AOU Città della Salute e della Scienza di Torino) ;
Carreño-Tarragona, Gonzalo (Hospital Universitario 12 de Octubre (Madrid)) ;
Patriarca, Andrea (AOU Maggiore della Carità (Itàlia)) ;
Al-Ali, Haifa Kathrin (University Hospital Halle) ;
Andrade-Campos, Marcio Miguel (Hospital del Mar (Barcelona, Catalunya)) ;
Palandri, Francesca (IRCCS Azienda Ospedaliero-Universitaria di Bologna) ;
Harrison, Claire (Guy's and St. Thomas' NHS Foundation Trust) ;
Foncillas, Maria Angeles (Hospital Universitario Infanta Leonor) ;
Osorio, Santiago (Hospital General Universitario Gregorio Marañón) ;
Koschmieder, Steffen (RWTH Aachen University) ;
Magro Mazo, Elena (Hospital Universitario Príncipe de Asturias (Alcalá de Henares, Madrid)) ;
Kiladjian, Jean-Jacques (Hospital Saint-Louis) ;
Bolaños Calderón, Estefanía (Hospital Clínico San Carlos (Madrid)) ;
Heidel, Florian H. (University Medicine Greifswald - Hematology) ;
Quiroz Cervantes, Keina (Hospital Universitario de Móstoles (Madrid)) ;
Griesshammer, Martin (University Clinic for Hematology (Alemanya)) ;
Garcia-Gutierrez, Valentin (Instituto Ramón y Cajal de Investigación Sanitaria (Madrid)) ;
Sanchez, Alberto Marin (Complejo Hospitalario Universitario de Albacete) ;
Hernandez-Boluda, Juan Carlos (Hospital Clínic Universitari (València)) ;
Lopez Abadia, Emma (Hospital General Universitario de Elche) ;
Carli, Giuseppe (Ospedale San Bortolo) ;
Sagues Serrano, Miguel (Hospital de Sant Joan Despí Moisès Broggi) ;
Kusec, Rajko (University Hospital Dubrava-School of Medicine University of Zagreb) ;
Xicoy, Blanca (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras) ;
Guenova, Margarita (National Specialised Hospital for Active Treatment of Hematological Diseases (Bulgària)) ;
Navas Elorza, Begona (Hospital Moncloa (Madrid)) ;
Angona, Anna (Hospital Universitari de Girona Doctor Josep Trueta) ;
Cichocka, Edyta (Nicolaus Copernicus Hospital (Polònia)) ;
Kulikowska de Nałęcz, Anna (Department of Hematology and Internal Diseases, State Hospital, Opole, Poland) ;
Cattaneo, Daniele (Università degli Studi di Milano) ;
Bucelli, Cristina (Foundation IRCCS Ca' Granda Ospedale Maggiore Policlinico) ;
Betti, Silvia (Università Cattolica del Sacro Cuore - Policlinico Universitario Agostino Gemelli IRCCS) ;
Borsani, Oscar (University of Pavia) ;
Cavalca, Fabrizio (Ospedale San Gerardo (Itàlia)) ;
Carbonell Curralo, Sara (Hospital Clínic i Provincial de Barcelona) ;
Curto-Garcia, Natalia (Guy's and St. Thomas' NHS Foundation Trust) ;
Benajiba, Lina (Hospital Saint-Louis) ;
Rambaldi, Alessandro (Università degli Studi di Milano) ;
Vannucchi, Alessandro Maria (University of Florence) ;
Universitat Autònoma de Barcelona
2022 - 10.1038/s41408-022-00749-8
Blood Cancer Journal, Vol. 12 (november 2022)
|
|
|
4.
|
|
20 p, 525.5 KB |
Managing hematological cancer patients during the COVID-19 pandemic : an ESMO-EHA Interdisciplinary Expert Consensus
/
Buske, Christian (University Hospital of Ulm (Alemanya)) ;
Dreyling, M. (Department of Medicine III at LMU Hospital) ;
Álvarez Larrán, Alberto (Institut d'Investigacions Biomèdiques August Pi i Sunyer) ;
Apperley, Jane (Imperial College London) ;
Arcaini, Luca (University of Pavia) ;
Besson, Caroline (UVSQ. Inserm. CESP) ;
Bullinger, Lars (Charité - Universitätsmedizin Berlin) ;
Corradini, Paolo (University of Milan) ;
Della Porta, Matteo Giovanni (Humanitas University) ;
Dimopoulos, Meletios (National and Kapodistrian University of Athens) ;
D'Sa, Shirley (University College London Hospitals NHS Foundation Trust) ;
Eich, H.T. (University of Muenster) ;
Foà, R. (Sapienza University) ;
Ghia, P. (Università Vita-Salute San Raffaele and IRCCS Ospedale San Raffaele) ;
da Silva, M.G. (Portuguese Institute of Oncology) ;
Gribben, J. (Queen Mary University of London) ;
Hajek, Roman (University of Ostrava) ;
Harrison, C. (Guy's and St Thomas' NHS Foundation Trust) ;
Heuser, M. (Hannover Medical School) ;
Kiesewetter, Barbara (Medical University of Vienna) ;
Kiladjian, Jean-Jacques (Université de Paris) ;
Kroeger, Nicolaus (University Hospital Hamburg-Eppendorf) ;
Moreau, Philippe (University Hospital Hotel-Dieu) ;
Passweg, Jakob R. (University Hospital Basel (Basilea, Suïssa)) ;
Peyvandi, Flora (University of Milan) ;
Rea, Delphine (Hôpital Saint-Louis) ;
Ribera, Jose-Maria (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras) ;
Robak, Tadeusz (Medical University of Lodz) ;
San-Miguel, J (Clínica Universidad de Navarra) ;
Santini, Valeria (University of Florence) ;
Sanz, G. (CIBERONC. IS Carlos III) ;
Sonneveld, P. (Erasmus MC Cancer Institute) ;
Von Lilienfeld-Toal, M. (Hans Knöll Institute) ;
Wendtner, Clemens-Martin (Ludwig-Maximilian University) ;
Pentheroudakis, G. (European Society for Medical Oncology) ;
Passamonti, Francesco (University of Insubria)
Background: The COVID-19 pandemic has created enormous challenges for the clinical management of patients with hematological malignancies (HMs), raising questions about the optimal care of this patient group. [...]
2022 - 10.1016/j.esmoop.2022.100403
ESMO open, Vol. 7 Núm. 2 (april 2022) , p. 100403
|
|
guest ::
email alert
or subscribe to the 
RSS feed.
